Costs for carbapenem-resistant versus carbapenem-sensitive acinetobacter baumannii infections

Yasmeen Lashari; Maftuchah Rochmanti; Abdul Khairul Rizki Purba; Hari Basuki Notobroto; Rosantia Sarassari; Kuntaman Kuntaman

doi:10.53730/ijhs.v6nS5.9213

Authors

Yasmeen Lashari Doctoral Program, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Maftuchah Rochmanti Division of Pharmacology, Department of Anatomy, Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Abdul Khairul Rizki Purba Division of Pharmacology, Department of Anatomy, Histology and Pharmacology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Hari Basuki Notobroto Department of Biostatistics and Population, Faculty of Public Health, Universitas Airlangga, Surabaya, Indonesia
Rosantia Sarassari Clinical Microbiology Specialist Programme, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Kuntaman Kuntaman Department of Medical Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia; Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

Keywords:

Acinetobacter baumannii, Carbapenem-resistance, Hospital cost, Indonesia, Infectious diseases

Abstract

The emergence and spread of Gram-negative bacteria namely Acinetobacter baumannii, is a serious public health challenge worldwide due to antibiotics resistance. Infections caused by this bacterium demonstrated significantly high economic burden. Nevertheless, economic burden of carbapenem resistant-Acinetobacter baumannii (CR-AB) and carbapenem susceptible -Acinetobacter baumannii (CS-AB) infections in Indonesia remain unknown. The aim of the study was to evaluate the cost of hospitalized patients associated with CR-AB and CS-AB infections. Methods: In a retrospective observational case control study, we evaluated the medical records of patients with CR-AB and CS-AB infections hospitalized in the Dr. Soetomo Hospital Surabaya, Indonesia between 2018-2021. Also, we retrieved the data of sex, clinical specimen, dates of admission and discharge. The study outcome was hospital costs such as antibiotic and diagnostic costs including radiology and lab investigations charges from the payer perspective. Results: The antibiotic and diagnostic costs for CR-AB infection was higher than CS-AB infection, US$ 1039.3 versus US$ 492.2 (p < 0.001). It showed that the CR-AB antibiotic cost was higher than CS-AB, US$ 77.2 versus US$ 19.7 (p < 0.001), and the CR-AB diagnostic cost was higher than CS-AB, US$ 882.1 versus US$ 463.1 (p < 0.05).

Downloads

Download data is not yet available.

References

Ayukekbong, J.A., Ntemgwa, M. and Atabe, A.N. (2017) ‘The threat of antimicrobial resistance in developing countries: Causes and control strategies’, Antimicrobial Resistance and Infection Control, 6(1), pp. 1–8. doi:10.1186/S13756-017-0208-X/TABLES/2.

Bernards, A., Frénay, H., … B.L.-A. journal of and 1998, undefined (no date) ‘Methicillin-resistant Staphylococcus aureus and Acinetobacter baumannii: an unexpected difference in epidemiologic behavior’, Elsevier [Preprint]. Available at: https://www.sciencedirect.com/science/article/pii/S0196655398001084 (Accessed: 8 March 2022).

Bimba, H., Roy, V., Batta, A. and Daga, M. (2020) ‘Drug utilization, rationality, and cost analysis of antimicrobial medicines in a tertiary care teaching hospital of Northern India: A prospective, observational study’, Indian journal of pharmacology, 52(3), pp. 179–188. doi:10.4103/IJP.IJP_225_19.

Dijkshoorn, L., Nemec, A. and Seifert, H. (2007) ‘An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii’, Nature reviews. Microbiology, 5(12), pp. 939–951. doi:10.1038/NRMICRO1789.

El Tahawy, A.T.A.E. and Khalaf, R.M.F. (2013) ‘Antibiotic Resistance Among Gram-Negative Non-Fermentative Bacteria at a Teaching Hospital in Saudi Arabia’, http://dx.doi.org/10.1179/joc.2001.13.3.260, 13(3), pp. 260–264. doi:10.1179/JOC.2001.13.3.260.

Falagas, M.E., Karveli, E.A., Siempos, I.I. and Vardakas, K.Z. (2008) ‘Acinetobacter infections: a growing threat for critically ill patients’, Epidemiology and infection, 136(8), pp. 1009–1019. doi:10.1017/S0950268807009478.

Hamidian, M. and Nigro, S.J. (2019) ‘Emergence, molecular mechanisms and global spread of carbapenem-resistant Acinetobacter baumannii’, Microbial Genomics, 5(10). doi:10.1099/MGEN.0.000306.

Huang, W., Zong, Z., Qiao, F., Chen, Y., Yin, W., Dong, P. and Lin, J. (2016) ‘DIRECT ECONOMIC BURDEN AND OUTCOMES AMONG PATIENTS WITH CARBAPENEM-RESISTANT ACINETOBACTER BAUMANNII INFECTION OR COLONIZATION’, Value in Health, 19(3), p. A215. doi:10.1016/J.JVAL.2016.03.1208.

Jiao, Y., Qin, Y., Liu, J., Li, Q., Dong, Y., Shang, Y., Huang, Y. and Liu, R. (2015) ‘Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization and predictors of mortality: a retrospective study’, Pathogens and Global Health, 109(2), p. 68. doi:10.1179/2047773215Y.0000000004.

Judd, W.R., Ratliff, P.D., Hickson, R.P., Stephens, D.M. and Kennedy, C.A. (2016) ‘Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients’, American Journal of Infection Control, 44(11), pp. 1275–1279. doi:10.1016/J.AJIC.2016.04.218.

Karuniawati, A., Lestari, Delly Chipta, Zorgani, A., Saharman, Y.R. and Lestari, Delly C (2011) ‘Detection of carbapenemase encoding genes in Enterobacteriace, Pseudomonas aeruginosa, and Acinetobacter baumanii isolated from patients at Intensive’, academia.edu, 2, pp. 101–106. Available at: https://www.academia.edu/download/40101790/Acta_Medica_Resistensi_Karbapenem_Genotip.pdf (Accessed: 6 March 2022).

Lautenbach, E., Synnestvedt, M., Weiner, M.G., Bilker, W.B., Vo, L., Schein, J. and Kim, M. (2009) ‘Epidemiology and impact of imipenem resistance in Acinetobacter baumannii’, Infection control and hospital epidemiology, 30(12), pp. 1186–1192. doi:10.1086/648450.

Lemos, E. V., de la Hoz, F.P., Alvis, N., Einarson, T.R., Quevedo, E., Castañeda, C., Leon, Y., Amado, C., Cañon, O. and Kawai, K. (2014) ‘Impact of carbapenem resistance on clinical and economic outcomes among patients with Acinetobacter baumannii infection in Colombia’, Clinical Microbiology and Infection, 20(2), pp. 174–180. doi:10.1111/1469-0691.12251.

LY, H., A, A., E, K., N, S., A, G. and PA, T. (2017) ‘Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia’, Clinical microbiology reviews, 30(1). doi:10.1128/CMR.MASTHEAD.30-1.

Maki, G. and Zervos, M. (2021) ‘Health Care–Acquired Infections in Low- and Middle-Income Countries and the Role of Infection Prevention and Control’, Infectious Disease Clinics of North America, 35(3), p. 827. doi:10.1016/J.IDC.2021.04.014.

Munoz-Price, L.S. and Weinstein, R.A. (2008) ‘Acinetobacter Infection’, New England Journal of Medicine, 358(12), pp. 1271–1281. doi:10.1056/NEJMRA070741.

Nordmann, P. and Poirel, L. (2019) ‘Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria’, Clinical Infectious Diseases, 69(Supplement_7), pp. S521–S528. doi:10.1093/CID/CIZ824.

Ozsurekci, Y., Aykac, K., Cengiz, A.B., Basaranoglu, S.T., Sancak, B., Karahan, S., Kara, A. and Ceyhan, M. (2017) ‘Bloodstream infections in children caused by carbapenem-resistant versus carbapenem-susceptible gram-negative microorganisms: Risk factors and outcome’, Diagnostic microbiology and infectious disease, 87(4), pp. 359–364. doi:10.1016/J.DIAGMICROBIO.2016.12.013.

Peleg, A.Y., Seifert, H. and Paterson, D.L. (2008) ‘Acinetobacter baumannii: emergence of a successful pathogen’, Clinical microbiology reviews, 21(3), pp. 538–582. doi:10.1128/CMR.00058-07.

Qureshi, Z.A., Hittle, L.E., O’Hara, J.A., Rivera, J.I., Syed, A., Shields, R.K., Pasculle, A.W., Ernst, R.K. and Doi, Y. (2015) ‘Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance’, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(9), pp. 1295–1303. doi:10.1093/CID/CIV048.

Rossi, I., Royer, S., Ferreira, M.L., Campos, P.A., Fuga, B., Melo, G.N., Machado, L.G., Resende, D.S., Batistão, D., Urzedo, J.E., Gontijo-Filho, P.P. and Ribas, R.M. (2019) ‘Incidence of infections caused by carbapenem-resistant Acinetobacter baumannii’, American journal of infection control, 47(12), pp. 1431–1435. doi:10.1016/J.AJIC.2019.07.009.

Saharman, Y.R., Karuniawati, A., Sedono, R., Aditianingsih, D., Sudarmono, P., Goessens, W.H.F., Klaassen, C.H.W., Verbrugh, H.A. and Severin, J.A. (2018) ‘Endemic carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex in intensive care units of the national referral hospital in Jakarta, Indonesia’, Antimicrobial Resistance and Infection Control, 7(1), pp. 1–12. doi:10.1186/S13756-017-0296-7/FIGURES/4.

Silvia Munoz-Price, L. and Weinstein, R.A. (2008) ‘Acinetobacter Infection’, N Engl J Med, 358, pp. 1271–81. Available at: www.nejm.org (Accessed: 8 March 2022).

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

The World Bank (2022) Population, total - Indonesia | Data. Available at: https://data.worldbank.org/indicator/SP.POP.TOTL?locations=ID (Accessed: 6 March 2022).

Tian, L., Tan, R., Chen, Y., Sun, J., Liu, J., Qu, H. and Wang, X. (2016) ‘Epidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: Factors related to the carbapenem resistance and patient mortality’, Antimicrobial Resistance and Infection Control, 5(1). doi:10.1186/S13756-016-0145-0.

Wagenvoort, J.H.T. and Joosten, E.J.A.J. (2002) ‘An outbreak Acinetobacter baumannii that mimics MRSA in its environmental longevity’, Journal of Hospital Infection, 52(3), pp. 226–227. doi:10.1053/JHIN.2001.1294.

World Heath Organization (2017) Global Priority List of Antibiotic Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/ (Accessed: 9 March 2022).

Yang, L., Xiao, Y. hong, Nie, Y., Zheng, Y. dong, Wang, J., Yan, Q., Hou, F., Sun, Z. yong and Lv, X. ju (2010) ‘[Impact of misuse of antimicrobial therapies on inpatient costs].’, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health Sciences, 42(3), pp. 279–283. Available at: https://europepmc.org/article/med/20559401 (Accessed: 8 March 2022).

Zhen, X., Chen, Y., Hu, X., Dong, P., Gu, S., Sheng, Y.Y. and Dong, H. (2017) ‘The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China’, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 36(10), pp. 1989–1994. doi:10.1007/S10096-017-3088-3.

Zhen, X., Lundborg, C.S., Sun, X., Gu, S. and Dong, H. (2020) ‘Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: A Multicenter Study in China’, Antibiotics (Basel, Switzerland), 9(8), pp. 1–13. doi:10.3390/ANTIBIOTICS9080514.